Laura J. van 't Veer, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Laura J. van 't Veer, PhD

Leader, Breast Oncology Program, and Director, Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center
Angela and Shu Kai Chan Endowed Chair in Cancer Research

vantveerl@cc.ucsf.edu

Phone: (415) 476-6023
Box 0808, UCSF
San Francisco, CA 94143-0808

View on UCSF Profiles

Cancer Center Membership

Program Member » Breast Oncology» Cancer Genetics

Research Summary

I am a world-renowned Molecular Biologist, and Leader of the Breast Oncology Program and Associate Director Applied Genomics at the HDFCCC. I am the former Head of Diagnostic Oncology of the Netherlands Cancer Institute, and inventor of MammaPrint. My research focuses on personalized medicine, and aims to advance patient management based on knowledge of the genetic makeup of the tumor as well as the genetic makeup of the patient. My laboratory at UCSF has a strong research line investigating human kinases and studies how kinase inhibitors elicit response and resistance. I am the UCSF Precision Medicine Platform convener for cancer. I chair the Biomolecular Committee of the I-SPY 2 trial ensuring CLIA compliant companion diagnostics. I am the Principal Investigator of the Athena Breast Health Network at UCSF, a 150,000-women cohort study evaluating new paradigms to enhance breast health for which I lead the targeted genome testing for 65,000 women for nine breast cancer susceptibility genes and a selection of ~100 known susceptibility Single Nucleotide Polymorphisms (SNPs). I am one of the PIs for the NIH Big Data to Knowledge Center on Genomics, facilitating worldwide standardization of sharing annotated genomics data. My role as chair of the AACR Diagnostic Policy committee and chair of the Scientific Advisory Committee of the National Biomarker Development Alliance underscores my lead role in this area.

Education

University of Amsterdam, Amsterdam, Netherlands, BSc, 1976-80, Biology, Molecular Oncology
University of Amsterdam, Amsterdam, Netherlands, MSc,1980-84, Experimental Oncology
University of Leiden, Leiden, Netherlands, PhD, 1984-89, Medicine, Oncogene Activation and Tumorigenesis


Professional Experience

  • 1989-1991
    Postdoctoral Fellow, Cancer Center, Harvard Medical School and Massachusetts General Hospital, Boston
  • 1992-1993
    Postdoctoral Fellow, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
  • 1993-2010
    Molecular Biologist, Department of Pathology, Division of Experimental Therapy, The Netherlands Cancer Institute
  • 1993-2010
    Group Leader, Molecular Pathology, Department of Pathology, Division of Experimental Therapy, The Netherlands Cancer Institute
  • 1993-2005
    Head DNA, Diagnostic Laboratories, Molecular Pathology, The Netherlands Cancer Institute
  • 1993-2005
    Head DNA, Diagnostic Laboratory, Family Cancer Clinic, The Netherlands Cancer Institute
  • 1997-2003
    Head, Family Cancer Clinic, The Netherlands Cancer Institute
  • 2002-2010
    Honorary Staff Member, Department of Surgery, Leiden University Medical Center, The Netherlands
  • 2004-2007
    Chief Operating Officer, Agendia BV, Amsterdam
  • 2007-2013
    Chief Research Officer, Agendia BV, Amsterdam
  • 2007-2010
    Clinical Division Head (ad interim), Division of Diagnostic Oncology, Clinical Departments of Pathology, Radiology, Nuclear Medicine, Clinical Chemistry, Family Cancer Clinic, The Netherlands Institute
  • 2008-2010
    Research Department Head, Department of Experimental Therapy (includes Molecular Pathology), The Netherlands Institute
  • 2008-2010
    Visiting Associate Professor, Cancer Center, University of California, San Francisco
  • 2010
    Visiting Associate Professor, Department of Pathology, University of California, San Francisco
  • 2010
    Visiting Associate Professor, Department of Radiology, University of California, San Francisco
  • 2010
    HS Clinical Instructor, Department of Laboratory Medicine, University of California, San Francisco
  • 2010-present
    Associate Director, Cancer Center, University of California, San Francisco
  • 2010-present
    Director, Applied Genomics, Cancer Center, University of California, San Francisco
  • 2010-present
    Professor, Department of Laboratory Medicine, University of California, San Francisco
  • 2010-present
    Professor, Department of Pathology, University of California, San Francisco
  • 2010-present
    Professor, Department of Radiology, University of California, San Francisco
  • 2011-present
    Faculty Member, Biomedical Sciences Graduate Program, University of California, San Francisco
  • 2011-present
    Faculty Member, Pharmaceutical Sciences and Pharmacogenomics Medicine, Clinical Chemistry, Family Cancer Clinic, University of California, San Francisco
  • 2011-present
    Angela and Shu Kai Chan Endowed Chair in Cancer Research, Department of Laboratory Medicine, University of California, San Francisco

Honors & Awards

  • 2005
    IARC Medal of Honor, Lyon, France
  • 2006
    Van der Scheuren award lecture for European Breast Cancer Research, EBCC5
  • 2007
    ESMO Lifetime Achievement Award for Translational Research in Breast Cancer
  • 2007, 2008
    Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award
  • 2009
    First Annual Harry and Edith Gladstein Award, Indiana University, School of Medicine
  • 2012
    AACC Outstanding Speaker Award
  • 2014
    Second Prize, European Union Prize for Women Innovators
  • 2015
    European Inventor Award, European Patent Office

Selected Publications

  1. Beumer I, Witteveen A, Delahaye L, Wehkamp D, Snel M, Dreezen C, Zheng J, Floore A, Brink G, Chan B, Linn S, Bernards R, van 't Veer L, Glas A. Equivalence of MammaPrint array types in clinical trials and diagnostics. Breast Cancer Res Treat. 2016 Apr; 156(2):279-87.
    View on PubMed
  2. Olow A, Chen Z, Niedner RH, Wolf DM, Yau C, Pankov A, Lee EP, Brown-Swigart L, van 't Veer LJ, Coppé JP. An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res. 2016 Apr 1; 76(7):1733-45.
    View on PubMed
  3. van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol. 2016 Feb 10; 34(5):409-18.
    View on PubMed
  4. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015; 17(1):73.
    View on PubMed
  5. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016 May; 141(2):386-401.
    View on PubMed
  6. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS One. 2015; 10(4):e0126988.
    View on PubMed
  7. van den Broek AJ, Schmidt MK, van 't Veer LJ, Tollenaar RA, van Leeuwen FE. Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis. PLoS One. 2015; 10(3):e0120189.
    View on PubMed
  8. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31.
    View on PubMed
  9. Drukker CA, Elias SG, Nijenhuis MV, Wesseling J, Bartelink H, Elkhuizen P, Fowble B, Whitworth PW, Patel RR, de Snoo FA, van 't Veer LJ, Beitsch PD, Rutgers EJ. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. Breast Cancer Res Treat. 2014 Dec; 148(3):599-613.
    View on PubMed
  10. Sawyers CL, van 't Veer LJ. Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research. Clin Cancer Res. 2014 Oct 1; 20(19):4978-81.
    View on PubMed
  11. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014; 9(9):e107255.
    View on PubMed
  12. van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK. Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. Eur J Hum Genet. 2015 May; 23(5):588-95.
    View on PubMed
  13. Li J, Lindström LS, Foo JN, Rafiq S, Schmidt MK, Pharoah PD, Michailidou K, Dennis J, Bolla MK, Wang Q, Van 't Veer LJ, Cornelissen S, Rutgers E, Southey MC, Apicella C, Dite GS, Hopper JL, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Blomqvist C, Muranen TA, Aittomäki K, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Hartikainen JM, Kataja V, Chenevix-Trench G. 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun. 2014; 5:4051.
    View on PubMed
  14. Wolf DM, Lenburg ME, Yau C, Boudreau A, van 't Veer LJ. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One. 2014; 9(2):e88309.
    View on PubMed
  15. Sapino A, Roepman P, Linn SC, Snel MH, Delahaye LJ, van den Akker J, Glas AM, Simon IM, Barth N, de Snoo FA, van 't Veer LJ, Molinaro L, Berns EM, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox CE. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn. 2014 Mar; 16(2):190-7.
    View on PubMed
  16. Meyer KB, O'Reilly M, Michailidou K, Carlebur S, Edwards SL, French JD, Prathalingham R, Dennis J, Bolla MK, Wang Q, de Santiago I, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Schmidt MK, Broeks A, Van 't Veer LJ, Hogervorst FB, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Lux MP, Ekici AB, Beckmann MW, Peto J, Dos Santos Silva I, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Zamora MP, Arias JI, Benitez J, Neuhausen S, Anton-Culver H, Ziogas A, Dur CC, Brenner H, Müller H, Arndt V, Stegmaier C, Meindl A, Schmutzler RK, Engel C, Ditsch N, Brauch H, Brüning T, Ko YD. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet. 2013 Dec 5; 93(6):1046-60.
    View on PubMed
  17. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14; 24(4):450-65.
    View on PubMed
  18. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Imielinsk M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22; 500(7463):415-21.
    View on PubMed
  19. Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van 't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer. 2013 Aug 15; 133(4):929-36.
    View on PubMed
  20. Kirchhoff T, Gaudet MM, Antoniou AC, McGuffog L, Humphreys MK, Dunning AM, Bojesen SE, Nordestgaard BG, Flyger H, Kang D, Yoo KY, Noh DY, Ahn SH, Dork T, Schürmann P, Karstens JH, Hillemanns P, Couch FJ, Olson J, Vachon C, Wang X, Cox A, Brock I, Elliott G, Reed MW, Burwinkel B, Meindl A, Brauch H, Hamann U, Ko YD. Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS One. 2012; 7(6):e35706.
    View on PubMed

Go to UCSF Profiles, powered by CTSI